tbuckley/cabot-search huggingface dataset:
Mouse Allergen Exposure in Urban Schools and Its Effect On Childhood Asthma Morbidity
Authors: Perdita Permaul, Carter R. Petty, William J. Sheehan, Sachin N. Baxi, Jonathan M. Gaffin, Lianne S. Kopel, Watcharoot Kanchongkittiphan, Ann Bailey, Chunxia Fu, Diane R. Gold, Wanda Phipatanakul
Journal: Journal of Allergy and Clinical Immunology (2013)
Phase I Study of a Decision Aid for Patients With Locally Advanced Non–Small-Cell Lung Cancer
Authors: M. D. Brundage, D. Feldman-Stewart, R. Cosby, R. Gregg, P. Dixon, Y. Youssef, D. Davies, W. J. Mackillop
Journal: Journal of Clinical Oncology (2001)

PURPOSE: Many patients with locally advanced non–small-cell lung cancer (LA-NSCLC) are eligible for combined-modality therapy (CMT; chemotherapy and radiotherapy). Although CMT offers slightly higher chances of survival than radiotherapy alone (RT), it also carries a higher probability of toxicity, raising the possibility that some patients may prefer to decline CMT. We report a pilot study of a decision aid designed for patients in this setting. PATIENTS AND METHODS: The aid included a structured description of the treatment options and trade-off exercises designed to help clarify the patient’s values for the relevant outcomes by determining the patient’s survival advantage threshold (SAT; the increase in survival conferred by CMT over RT that the patient deemed necessary for choosing CMT). Additional outcome measures included each patient’s strength of treatment preference, decisional conflict, objective understanding of survival information, and decisional role preference. RESULTS: Twenty-seven patients met the eligibility criteria for the study. Of these, seven declined the decision aid because they had a clear treatment preference. The remaining 20 participants completed the decision aid; 18 chose CMT, and two chose RT. All 20 patients wished to participate in the decision to some extent. All patients reported that using the decision support was useful to them and recommended its use for others. No patient or physician reported that the aid interfered with the physician-patient relationship. Patients’ 3-year SATs and median SATs were each strongly correlated with their strengths of treatment preference (ρ = 0.83, P &lt; .001 and ρ = 0.67, P = .02, respectively). For all but one patient, either their 3-year or median survival threshold was consistent with their final treatment choice. Ten patients reported a stronger treatment preference after using the decision aid. CONCLUSION: We conclude that implementing the decision-aid for patients with LA-NSCLC is feasible, that it demonstrates convergent validity, and that it is favorably evaluated by patients and their physicians. The aid seems to help patients understand the benefits and risks of treatment and to choose the treatment that is most consistent with their values. Further evaluation of the aid is warranted.
Research, policy and practice related to survivors of childhood, adolescent and young adult cancers in British Columbia (BC), Canada: A population-based approach
Authors: P. C. Rogers, A. Broemeling, S. L. Pritchard, K. Goddard, L. Xie, B. Poole, S. Sheps, M. L. McBride
Journal: Journal of Clinical Oncology (2007)

9539 Background and Purpose: Prevalence of long term survivors of pediatric, adolescent and young adult cancers is increasing. In BC we are using a multidimensional population approach to address research and care for these survivors. Information on trends in prevalence of survivors and use of physician services are presented. Methods: We have identified a cohort of patients under 25, diagnosed from population registries since 1970, and linked their records with person-based longitudinal records of health utilization. Results: Prevalence rate of cancer survivors aged 0–59 years, originally diagnosed under age 25, increased 5 fold between 1975 and 2005, from 26 per 100,000 to 147 per 100,000; 78% were aged 20 or older. A total subgroup of 3,787 individuals surviving five years or more, diagnosed between 1970 and 1995, were identified; 2,590 (68%) of these were linked to physician visit records (excluding visits within BC's Children's Hospital) from 1986 to 2000. In year 2000, 77% of survivors had at least one physician visit; 75% of survivors saw a family physician (FP), and 44% of survivors visited a specialist physician with a specialty that could be related to a late effect. Between 1986 and 2000 survivor prevalence increased 3.3% per year; total visits by survivors to FPs increased by 11.6% per year and by 10.6% per year to specialists. In 1986, 66% of physician visits were for patients older than 20 which increased to 79% by 2000. A provincial pediatric oncology network consisting of oncologists and community care representatives has been established to implement changes to long-term follow up policy. Conclusion: The prevalence rate and utilization of health services among survivors of childhood, adolescent and young adult cancers continues to escalate. Research results, along with other published literature, will inform the development of policy and practice within the BC Network. No significant financial relationships to disclose.
Phase I/II study of intermittent all-trans-retinoic acid, alone and in combination with interferon alfa-2a, in patients with epidemic Kaposi's sarcoma.
Authors: J Bailey, J M Pluda, A Foli, M W Saville, S Bauza, P C Adamson, R F Murphy, R B Cohen, S Broder, R Yarchoan
Journal: Journal of Clinical Oncology (1995)

PURPOSE A phase I/II study of oral all-trans-retinoic acid (ATRA; tretinoin), administered every other week alone and then in combination with interferon (IFN) alfa-2a, was undertaken to evaluate the activity, toxicity, and pharmacokinetics of this regimen in patients with human immunodeficiency virus (HIV)-associated Kaposi's sarcoma (KS). PATIENTS AND METHODS Thirteen patients with HIV-associated KS, eight of whom had more than 100 CD4 cells/microL, were entered. The protocol initially called for patients to receive 150 mg/m2/d of ATRA every other week. However, this regimen was associated with headaches, and the initial dose of ATRA was reduced to 40 mg/m2/d orally in three divided doses, increasing to a maximum of 100 mg/m2/d. After 12 weeks, IFN alfa-2a could be added. RESULTS The principal toxicities from ATRA were headaches (12 patients) and dry skin or lip (seven patients). Of 12 assessable patients, 10 had progressive disease and two had stable disease on ATRA alone. One of eight assessable patients who went on to receive ATRA plus IFN alfa-2a had partial response (PR). There were no overall changes in the serum HIV p24 antigen (Ag) level or CD4 count during treatment with ATRA alone. Peak ATRA levels decreased during the week of continuous ATRA therapy, but rebounded when treatment was resumed after a week without the drug. CONCLUSION Intermittent ATRA therapy was reasonably well tolerated and provided a means to circumvent the low plasma exposure found with continuous ATRA therapy. However, we were unable to document antitumor activity in patients with HIV-associated KS.
EphA2 and EFNA1 are transcriptional targets of EGFR in gefitinib-sensitive non-small cell lung cancer cell lines
Authors: Kuicheon Choi, Jonathan Kurie
Journal: Cancer Research (2007)

AACR Annual Meeting-- Apr 14-18, 2007; Los Angeles, CA

4409 

EGF receptor (EGFR) mutations are observed in the tumors of a subset of non-small cell lung cancer (NSCLC) patients, and several clinical trials with EGFR tyrosine kinase inhibitors, Gefitinib and Erlotinib, showed significant response rates in these patients. However, the mechanisms by which these drugs induce tumor shrinkage are poorly understood. To address this question, microarray gene expression profiling was performed on 5 gefitinib-resistant NSCLC (3 with wild-type and 2 with mutant-type EGFR) and 3 gefitinib-sensitive NSCLC (all with mutant type EGFR) cell lines to uncover the immediate responses associated with sensitivity to gefitinib. The data for gene expression profiling was analyzed in two ways; first, by comparing gefitinib-resistant versus -sensitive (including only EGFR-mutant cell lines); second, by comparing gefitinib-resistant versus -sensitive (including both EGFR-wild-type and mutant cell lines). Using strict criteria, we have identified 130 genes from the first and 135 genes from the second comparisons to be significantly modulated by gefitinib. To validate the data, 50 genes were selected for SYBR-Green based quantitative Real-time PCR, and 46 genes among the 50 were confirmed to be similarly regulated. The Ingenuity Pathway Analysis software was used to sort those genes by their biological functions, which revealed genes involved in the regulation of cell cycle, apoptosis, cell morphology, cellular growth and proliferation, gene transcription, and cell signaling. EphA2 and EFNA1 were two genes found to be regulated only in gefitinib-sensitive cell lines. Gefitinib increased the expression of EFNA1 3-fold and decreased the expression of EphA2 7 to 20-fold. These changes were also observed at the protein level by western blotting. The expression of other EFNA1 receptors did not change. Treatment with 5ug/ml of EphA2 antagonist, recombinant EphA2/Fc, decreased cell viability approximately 30% in sensitive but not in resistant cell lines. Additional experiments are underway to examine the role of EphA2 and EFNA1 in gefitinib response.
Abstract 16: Variability in Treated Versus Untreated Out-of-Hospital Cardiac Arrest Episodes Across the Resuscitation Outcomes Consortium
Authors: Steven C Brooks, Robert H Schmicker, Sheldon Cheskes, Jim Christenson, Alan Craig, Mohamud Daya, Peter J Kudenchuk, Graham Nichol, Dana Zive, Laurie J Morrison
Journal: Circulation (2014)

Emergency medical service (EMS) protocols, patient presentation, and provider judgment may influence whether resuscitation is initiated for patients with out-of-hospital cardiac arrest (OHCA). Variability in the proportion of OHCA patients who receive resuscitation attempts could distort comparative analyses. We aimed to determine whether the proportion of OHCA cases having resuscitation attempted varied between study sites within the Resuscitation Outcomes Consortium (ROC). We also explored the relationship between the proportion of patients that were treated and the reported survival by ROC site. This was a retrospective study using the ROC Epistry database. We considered all non-traumatic cardiac arrests from 1/1/2006 to 12/31/2010 for inclusion. We excluded cases from EMS agencies that did not participate in the ROC PRIMED trial and from time periods with incomplete case capture. The proportion of patients who had resuscitation initiated by EMS personnel was the primary outcome. We used Chi-square to ...
Abstract 2123: ECG Markers to Predict Cardiovascular Death: Heart Rate Variability, Deceleration Capacity and Morphologic Variability in Non-ST-Elevation ACS from the MERLIN-TIMI 36 Trial
Authors: Zeeshan Syed, Benjamin M Scirica, David A Morrow, Satishkumar Mohanavelu, Collin M Stultz, John V Guttag
Journal: Circulation (2008)

Background : ECG parameters such as heart rate variability (HRV), deceleration capacity (DC) and morphologic variability (MV) may help identify patients at high risk post-ACS. These techniques measure specific aspects of cardiac health. HRV studies sympathovagal modulation of heart rate, DC extends heart rate turbulence by measuring acceleration-deceleration patterns, and MV quantifies variability in the shape of the ECG signal associated with myocardial instability. We assessed the relationship among HRV, DC and MV, and cardiovascular (CV) death after NSTEACS. Methods : HRV, DC and MV were calculated in 2164 placebo patients in the MERLIN-TIMI 36 trial using 24 hour Holter ECG after randomization. For each measure, patients were split into high and low risk groups (cutpoints chosen from literature: HRV LF/HF=1.2 [33.5%], DC&lt;2.5 ms [9.7%], MV LF/HF=3.7 [11.6%]). Mean clinical follow-up was 1 year. Results : Each ECG variable was associated with CV mortality when included alone in the multivariate model with the TIMI risk score (TRS) at 30 days (HR 2.8 p=0.008 for HRV, HR 4.5 p&lt;0.001 for DC and HR 5.1 p&lt;0.001 for MV) and at 1 year (HR 2.9 p&lt;0.001 for HRV, HR 2.8 p&lt;0.001 for DC and HR 2.4 p&lt;0.001 for MV). There was a stepwise increase in the risk of CV death at 1 year according to the number of abnormal ECG parameters, even after adjusting for the TRS. Conclusions : HRV, DC and MV are significantly associated with CV death both in the short and medium term following NSTEACS. Patients with multiple ECG abnormalities are at highest risk. These ECG parameters may provide complementary information to better risk-stratify patients following ACS.
MicroRNA-26a suppresses epithelial-mesenchymal transition in human hepatocellular carcinoma by repressing enhancer of zeste homolog 2
Authors: De-Ning Ma, Zong-Tao Chai, Xiao-Dong Zhu, Ning Zhang, Di-Hua Zhan, Bo-Gen Ye, Cheng-Hao Wang, Cheng-Dong Qin, Yi-Ming Zhao, Wei-Ping Zhu, Man-Qing Cao, Dong-Mei Gao, Hui-Chuan Sun, Zhao-You Tang
Journal: Journal of Hematology & Oncology (2016)

Our previous study reported that microRNA-26a (miR-26a) inhibited tumor progression by inhibiting tumor angiogenesis and intratumoral macrophage infiltration in hepatocellular carcinoma (HCC). The direct roles of miR-26a on tumor cell invasion remain poorly understood. In this study, we aim to explore the mechanism of miR-26a in modulating epithelial-mesenchymal transition (EMT) in HCC. In vitro cell morphology and cell migration were compared between the hepatoma cell lines HCCLM3 and HepG2, which were established in the previous study. Overexpression and down-regulation of miR-26a were induced in these cell lines, and Western blot and immunofluorescence assays were used to detect the expression of EMT markers. Xenograft nude mouse models were used to observe tumor growth and pulmonary metastasis. Immunohistochemical assays were conducted to study the relationships between miR-26a expression and enhancer of zeste homolog 2 (EZH2) and E-cadherin expression in human HCC samples. Down-regulation of miR-26a in HCCLM3 and HepG2 cells resulted in an EMT-like cell morphology and high motility in vitro and increased in tumor growth and pulmonary metastasis in vivo. Through down-regulation of EZH2 expression and up-regulation of E-cadherin expression, miR-26a inhibited the EMT process in vitro and in vivo. Luciferase reporter assay showed that miR-26a directly interacted with EZH2 messenger RNA (mRNA). Furthermore, the expression of miR-26a was positively correlated with E-cadherin expression and inversely correlated with EZH2 expression in human HCC tissue. miR-26a inhibited the EMT process in HCC by down-regulating EZH2 expression.
Taxanes in metastatic breast cancer patients with impaired liver function
Authors: L. B. Michaud, E. Rivera, T. Madden, L. Esparza-Guerra, D. J. Booser, M. C. Green, G. R. Bradshaw, G. N. Hortobagyi, V. Valero
Journal: Journal of Clinical Oncology (2005)

609 Taxanes are eliminated through the hepatobiliary route, and published guidelines for administration in patients (pts) with liver dysfunction (LD) have not been clinically useful. We prospectively assessed a method for safe administration of the taxanes in metastatic breast cancer (MBC) pts with differing degrees of LD as measured by standard liver function tests and attempted to correlate this dosing strategy with toxicities and standard pharmacokinetic (PK) measures of the two available taxanes, paclitaxel (pac) and docetaxel (doc). METHODS: Eligible pts were those with hepatic metastases from MBC who were candidates for pac or doc and who met the following criteria: Group I) total bilirubin (TBili) normal and alanine aminotransferase (ALT)/aspartate aminotransferase (AST) 1.5–2.5 x upper limit of normal (ULN) and alkaline phosphatase (Alk Ph) ≥ 2.5 x ULN; Group II) TBili normal and ALT/AST 2.5–5 x ULN and/or Alk Ph ≥ 2.5 x ULN in the absence of bone metastases; Group III) TBili 1.5–3 x ULN and ALT/AST 1.5–2.5 x ULN and/or Alk Ph ≥ 2.5 x ULN; Group IV) TBili 1.5–3 x ULN and ALT/AST 2.5–5 x ULN and/or Alk Ph ≥ 2.5 x ULN; Group V) TBili > 3 x ULN and any ALT/AST/Alk Ph or ALT/AST > 5 x ULN and any TBili or Alk Ph. All other causes for LD were ruled out, and bile duct obstruction was surgically or endoscopically corrected, if possible, prior to study entry. Chemotherapy doses were as outlined in the table below. All pts signed informed consent for participation. RESULTS: 35 pts were enrolled (12 on pac, 23 on doc). Grade 3/4 toxicity per patient included fatigue (pac=42%, doc=57%), myalgias (pac=33%, doc=22%), infection w/neutropenia (pac=25%, doc=22%), infection w/o neutropenia (pac=25%, doc=4%), diarrhea (pac=17%, doc=4%), mucositis (pac=8%, doc=4%), and peripheral neuropathy (pac=0%, doc=4%). Initial analyses indicate that PK data did not correlate with toxicity. CONCLUSIONS: The taxanes can be administered to pts with MBC and LD following dose attenuation as utilized in this study. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Aventis, Bristol-Myers Squibb Aventis, Bristol-Myers Squibb, sanofi-aventis Aventis, Bristol-Myers Squibb
<i>Day of Sounds</i>
Authors: Jeanette M. Smith
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Diffuse Vasculitis and Death after Hyperimmunization with Pertussis Vaccine
Authors: William B. Bishop, Rodney F. Carlton, Louis L. Sanders
Journal: New England Journal of Medicine (1966)

REPEATED immunization in man is becoming an ever increasing worldwide practice. Complications after these repeated antigenic challenges have generally been minimal and negligible in human beings. Severe complications have been observed, however, in animals. Amyloidosis in horses receiving intensive immunizations with diphtheria toxin,1 vasculitis, glomerulonephritis and granuloma of the spleen after repeated injections of horse serum in rabbits2 and joint as well as cardiac valvular lesions after injections of the polysaccharide from Klebsiella pneumoniae 3 have been the chief complications. Reports of complications in man are scarce. Recently, Peeler, Kadull and Cluff4 reported on a careful analysis of a group of . . .
Germline mutations in early-onset or hereditary breast cancer from the Middle East.
Authors: Makia J Marafie, Rabea Al-Temaimi, Andre Megarbane, Fahd Al-Mulla
Journal: Journal of Clinical Oncology (2015)

20 Background: Breast cancer is the most common cancer affecting women of Middle Eastern origin. Epidemiologically, breast cancer in the Middle East clusters in families and usually affects women a decade younger than Western women. This dilemma is compounded by the lack of curated databases and ambitious studies that address the roles genetic or genomic may play in breast cancer. Methods: We have exome sequenced 60 Middle Eastern women with moderate and strong family history of cancer or young women without significant family history of cancer. DNA extracted from peripheral blood of patients and matching normal Middle Eastern women without history of familial or sporadic cancers, were subjected to whole-exome sequencing using the HiSeq 2500 Illumina platform and MLPA to map major breast cancer–activating genetic defects. Results: Several novel BRCA1/2 mutations were identified in the minority of these women. However, other complex mutations in non-BRCA1/2 genes appear to play a more subtle role in breast cancer in the Middle Eastern women. Germline mutations in TP-53, BARD1 and mismatch repair genes were more frequent than expected by chance. Conclusions: BRCA1/2 gene mutations are not a significant cause of heritable cancers in the Middle East. The region may benefit from a well-curated region-specific database accessible to clinicians and scientists where clinical and variants information can be deposited from all over the Middle East.
Pathologic classification as a predictive factor in advanced non-small cell lung cancer.
Authors: E. Richardet, M Richardet, L Perelli, I Magri, N Castagneris, M. Cortes
Journal: Journal of Clinical Oncology (2010)

Article Tools Lung Cancer (Metastatic) Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/jco.2010.28.15_suppl.e18075 Journal of Clinical Oncology - published online before print May 20, 2010 Pathologic classification as a predictive factor in advanced non-small cell lung cancer. E. RichardetxE. RichardetSearch for articles by this author , M RichardetxM RichardetSearch for articles by this author , L PerellixL PerelliSearch for articles by this author , I MagrixI MagriSearch for articles by this author , N CastagnerisxN CastagnerisSearch for articles by this author , M. CortesxM. CortesSearch for articles by this author Show More Instituto Oncologico Cordoba, Cordoba, Argentina https://doi.org/10.1200/jco.2010.28.15_suppl.e18075 Abstract Abstract e18075 Background: Platinum-based doublets with the addition of third-generation drugs have become a "standard" in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC). A new trial has shown survival based on histology differences, with results that need to be ratified to guide an appropriate therapeutic behavior. The objective of this study is to determine whether a difference exists in progression-free survival (PFS) and overall survival (OS) in relation to histological types. Methods: We analyzed retrospectively the medical records of 186 patients with advanced NSCLC (stages IIIB and IV) from 2004 to 2009. Two groups were established: Adenocarcinoma (group A) and squamous cell carcinoma (group B). Patients received cisplatin 75 mg/m2 on day 1 and gemcitabine 1,000 mg/m2 on days 1, 8 and 15 every 28 days (GC) (n = 79) OR carboplatin AUC 6 mg/mL/min and paclitaxel 175 mg/m2 on day 1 every 21 days (PC) (n = 107). Survival curves were made up by Kaplan-Maier method and compared using the log-rank test. Results: The PFS for group A treated with PC and GC was 6.4 and 8.7 months (p = 0.03); for group B was 7.6 and 8.2 months respectively (p = 0.55).The OS in group A was 9.9 (PC) and 12.1 (GC) months (p = 0.21), while in group B was 9.7 (PC) and 11.2 (GC) months (p = 0.40). Regardless of histology, the PFS for patients treated with PC and GC were 6.7 and 8.5 months (p = 0.02) and the OS was 9.9 and 11.7 months respectively (p = 0.16). Conclusions: OS are similar on both groups. A subsequent analysis showed that, whatever the histological type is, the GC scheme significantly prolongs PFS, also providing greater OS, suggesting a higher effectiveness of this treatment when compared to PC. Adenocarcinoma treated with GC shows a major PFS. This is the evidence that histology is a predictive factor in NSCLC. No significant financial relationships to disclose. © 2010 by American Society of Clinical Oncology